Skip to main content
. Author manuscript; available in PMC: 2009 Jul 15.
Published in final edited form as: J Immunol. 2008 Jul 15;181(2):1345–1356. doi: 10.4049/jimmunol.181.2.1345

Table III.

DC subsets in the lungs

Treatmentb
L-Selectinc
P1d P2e Naive vs. Treatment
DC Subset a Ad2/β Gal-2 LPS −/− +/+ −/− vs. +/+ −/− +/+
Lymphoid 57.6 ± 2.0 54.4 ± 4.4 NS - -
+ 44.5 ± 3.7 33.9 ± 2.7 0.035 0.007 <0.001
+ 53.5 ± 2.9 38.6 ± 2.3 <0.001 NS 0.004
Plasmacytoid 10.2 ± 0.7 14.2 ± 0.8 0.001 - -
+ 17.3 ± 1.5 17.1 ± 1.6 NS <0.001 NS
+ + 11.9 ± 1.4 14.5 ± 1.5 NS NS NS
Myeloid 11.4 ± 0.9 14.3 ± 2.0 NS - -
+ 17.5 ± 2.9 17.6 ± 3.8 NS NS NS
+ + 17.8 ± 1.3 23.4 ± 1.3 0.006 <0.001 <0.001
Conventional 17.8 ± 1.0 24.0 ± 2.4 0.025 - -
+ 33.8 ± 3.6 46.3 ± 3.9 0.029 <0.001 <0.001
+ + 19.5 ± 2.5 31.8 ± 3.0 0.004 NS NS
a

Pulmonary DCs were gated on lymphocytes that were CD11c TCRα β.

b

DCs were derived from naive, Ad2/βGal-2-dosed, or Ad2/βGal-2 + LPS-dosed mice.

c

−/− = L-Selectin-deficient mice; +/+ = B6 mice. Data presented as mean ± SEM.

d

p-value between L-Sel−/− and L-Sel+/+ DC subsets (n = 10 mice/group); NS = not significant.

e

p-value between treatments within L-Sel−/− or L-Sel+/+ groups.